Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102

Neoadjuvant docetaxel, oxaliplatin, and S‑1 therapy for patients with large type 3 or type 4 gastric cancer: short‑term outcomes of a multicenter, phase II study (OGSG1902)

A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2‐positive Chemotherapy‐refractory Gastric Cancer (OGSG1203 HERBIS‐5): Final Results

Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)

Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S‑1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)

Phase I study of neoadjuvant chemoradiotherapy with S‑1 for clinicallyresectable type 4 or large type 3 gastric cancer in elderly patients aged75 years and older (OGSG1303)

Short‑term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)

Five‑year outcomes of a phase II study of adjuvant chemotherapy with S‑1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002)

PhaseⅡstudy of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)